Core Viewpoint - On May 7, the Shanghai Composite Index rose by 0.8%, the Shenzhen Component Index increased by 0.22%, and the ChiNext Index gained 0.51%, indicating a positive market trend for the day [2]. Group 1: Stock Performance - Tianyu Shuke (002354.SZ) saw the highest net inflow of funds, amounting to 214 million yuan, representing 7.7% of its total trading volume, and closed with a gain of 10.05% and a turnover rate of 24.92% [2][4]. - Changshan Pharmaceutical (300255.SZ) experienced the largest net outflow of funds, totaling 192 million yuan, which accounted for 7.18% of its total trading volume, and closed up by 20.02% with a turnover rate of 10.63% [6][8]. Group 2: Institutional and Northbound Fund Activity - On May 7, 19 stocks on the Dragon and Tiger list saw institutional participation, with a total net purchase of approximately 94.99 million yuan, where institutions net bought 8 stocks and net sold 11 stocks [6][10]. - The stock with the highest net purchase by institutions was Tianyuan Dike (300047.SZ), which closed up by 8.46% with a turnover rate of 48.9% [7]. - Northbound funds participated in 12 stocks on the Dragon and Tiger list, with a total net purchase of 246 million yuan, where the highest net purchase was in Zongshen Power (001696.SZ) at 54.62 million yuan [11]. Group 3: Divergence in Fund Flows - Both institutions and northbound funds jointly net bought Tianyuan Dike and Changshan Pharmaceutical, while they jointly net sold Construction Industry and Suoao Sensor [12][13]. - In Tianyu Shuke, there was a divergence where institutions net sold 13.05 million yuan while northbound funds net bought 33.67 million yuan [12].

证券代码：300255 证券简称：常山药业 公告编号：2025-19 河北常山生化药业股份有限公司 2．公司艾本那肽注射液拟用于减重适应症的临床试验申请已经获得国家药监局 受理，目前处于审评阶段，能否获得临床试验批准通知书存在不确定性。艾本那肽 即使获批开展减重适应症临床试验研究，临床试验进度及结果、未来产品市场竞争 形势均存在诸多不确定性。 3．艾本那肽是以公司控股子公司常山凯捷健生物药物研发（河北）有限公司（以 下简称"常山凯捷健"）为主体进行的研发注册，公司持有常山凯捷健51%股份，其 净利润中由上市公司股东享有的份额为51%，由少数股东享有的份额为49%。常山凯 捷健未来实现盈利后，公司不能享有其实现的全部净利润。 4．公司 2024 年度营业收入为 103,081.05 万元，较上年下降 26.92%；归属于上 市公司股东的净利润为亏损 24,947.77 万元；基本每股收益为亏损 0.27 元/股。具体 情况详见公司 2025 年 4 月 29 日于巨潮资讯网站发布的《2024 年年度报告》（公告编 号 2025-11），并请关注其中详述公司经营所面临的风险。 5．公司股票连续两个交易日（2025 ...

Group 1 - The core point of the article is that Changshan Pharmaceutical's stock price has been experiencing significant fluctuations, with multiple instances of hitting the daily limit up, attributed to investor interest in its weight loss drug Aibennate [1] - The company reported a stock price increase of 11.89% the previous day, indicating strong market interest [1] - Aibennate is an innovative drug developed by Changshan Pharmaceutical's subsidiary, Changshan Kaijie Health, and is currently in the registration phase [1] Group 2 - The company confirmed that there is no new progress regarding Aibennate, addressing investor inquiries [1] - Regarding two other anti-tumor targeted original new drugs, CSCJC3456 and CSCJC4523, the company stated that they are in Phase I clinical trials and preclinical research stages, respectively [1]

Core Viewpoint - Changshan Pharmaceutical's stock price has reached a historical high, driven by investor interest in its weight loss drug, Aibennate, despite the company facing ongoing performance challenges [1][3]. Group 1: Company Developments - Aibennate, developed by Changshan Pharmaceutical's subsidiary, is a novel GLP-1 receptor agonist aimed at treating type 2 diabetes and potentially aiding in weight loss [2]. - The National Medical Products Administration (NMPA) has accepted the new drug application (NDA) for Aibennate, indicating progress in its regulatory pathway [2]. - The company has acknowledged the competitive landscape for GLP-1 drugs, with several already approved for weight loss, which may impact Aibennate's market potential [2]. Group 2: Financial Performance - In 2024, Changshan Pharmaceutical reported a revenue of 1.031 billion yuan, a year-on-year decline of 26.92%, and a net profit attributable to shareholders of -249 million yuan, indicating a loss reduction compared to previous periods [3]. - For Q1 2025, the company achieved a revenue of 259 million yuan, down 12.10% year-on-year, but reported a net profit of 3.78 million yuan, reflecting a significant increase of 106.13% [3]. - The decline in revenue is primarily attributed to changes in the market structure due to centralized procurement policies affecting the sales of its main product, low molecular weight heparin calcium injection [3].

Core Viewpoint - Changshan Pharmaceutical is actively implementing a development strategy focused on expanding advantages, addressing shortcomings, developing new products, innovating drugs, and pursuing external growth in response to changes in the heparin industry [1][2]. Group 1: Business and Product Structure - Changshan Pharmaceutical is one of the few domestic companies with a complete heparin product industrial chain, engaging in the research, production, and sales of heparin crude products, active pharmaceutical ingredients, and formulations [1]. - The company’s main heparin products include heparin sodium crude, heparin sodium API, low molecular weight heparin calcium API, and various heparin injection solutions [1]. - The low molecular weight heparin calcium injection has maintained a leading market share for several years but has seen a decline in sales due to the impact of centralized procurement policies [1]. Group 2: Financial Performance - In the reporting period, Changshan Pharmaceutical achieved a revenue of 1.031 billion yuan, with low molecular weight heparin API contributing 145 million yuan, a year-on-year increase of 31.82% [2]. - Revenue contributions from ordinary heparin API and low molecular weight heparin formulations were 242 million yuan and 454 million yuan, respectively, while platform heparin formulations saw an 8.33% year-on-year growth to 54 million yuan [2]. Group 3: Innovation and R&D - The company views innovative drug research and development as key to overcoming current challenges, with a focus on the GLP-1 long-acting formulation, Aibennate injection, which has received acceptance for its marketing application from NMPA [2]. - If Aibennate is approved and launched, it is expected to reduce the company's reliance on heparin business for revenue and enhance profitability and risk resilience [2]. - Changshan Pharmaceutical is also advancing the development of two anti-tumor targeted original new drugs, CSCJC3456 and CSCJC4523, with CSCJC3456 having received NMPA approval for clinical trials in late-stage solid tumors [3]. Group 4: Future Strategy - For 2025, the company plans to maintain the sales of low molecular weight heparin formulations while focusing on increasing sales of heparin crude and API products [3]. - The company aims to actively promote the clinical progress and market launch of innovative drugs like Aibennate and CSCJC3456, with the goal of enhancing overall profitability [3].

证券代码：300255 证券简称：常山药业 公告编号：2025-17 河北常山生化药业股份有限公司 关于提请股东大会授权董事会办理以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券发 行上市审核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》等 相关规定，河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第六届董事会第二次会议、第六届监事会第二次会议，审议通过《关 于提请股东大会授权董事会办理以简易程序向特定对象发行股票的议案》，同意 公司董事会提请股东大会授权董事会办理以简易程序向特定对象发行融资总额 不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限为自 2024 年度股东大会通过之日起至 2025 年度股东大会召开之日止。 本议案尚需提交股东大会审议，现将有关情况公告如下： 一、具体内容 （一）发行股票的种类和面值 本次发行股票的种类为境内上市人民币普通股（A 股），每股面值人民币 1.00 ...

河北常山生化药业股份有限公司 关于召开 2024 年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）第六届董事会第二次 会议经审议通过决定于 2025 年 5 月 19 日（星期一）召开公司 2024 年度股东大 会，现就有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次 本次股东大会为 2024 年度股东大会。 （二）召集人 证券代码：300255 证券简称：常山药业 公告编号：2025-18 本次股东大会的召集人为公司董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等相关法律法规和《公司章程》的有关 规定。 （四）会议召开的日期、时间 1．现场会议时间：2025 年 5 月 19 日下午 14:00。 2．网络投票时间：2025 年 5 月 19 日。 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 19 日 9:15—9:25、9:30—11:30、13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为：202 ...

河北常山生化药业股份有限公司（以下简称"公司"）第六届监事会第二次 会议于 2025 年 4 月 28 日在公司办公楼会议室以现场方式召开。本次会议于 2025 年 4 月 18 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会 的各位监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实 际参与表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，本次监事会 的召开符合《公司法》及《公司章程》等法律法规的规定。 本次会议经过充分讨论，以记名投票方式审议通过如下议案： 一、审议通过《关于<公司 2024 年度监事会工作报告>的议案》 详细内容详见公司同日发布的《2024 年度监事会工作报告》。 表决结果：3 票同意；0 票反对；0 票弃权。 本议案需提交股东大会审议。 证券代码：300255 证券简称：常山药业 公告编号：2025-9 河北常山生化药业股份有限公司 第六届监事会第二次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 二、审议通过《关于<公司 2024 年度财务决算报告>的议案》 监事会认为：公司《2 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-8 河北常山生化药业股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 表决结果：6 票同意；0 票反对；0 票弃权。 河北常山生化药业股份有限公司（以下简称"公司"）第六届董事会第二次会 议于 2025 年 4 月 28 日在公司会议室以现场方式召开。本次会议于 2025 年 4 月 18 日以邮件方式向公司全体董事发出会议通知。会议应出席董事 6 名，实际出 席董事 6 名，会议由公司董事长高晓东先生主持，公司监事及高级管理人员列席 了本次会议。本次董事会的召开符合《公司法》及《公司章程》等法律法规的规 定。 会议以记名投票方式对各项议案进行表决，审议通过如下议案： 一、审议通过《关于<公司 2024 年度董事会工作报告>的议案》 公司董事对 2024 年度履行职责的情况以及相关工作内容进行了总结，编制 了《2024 年度董事会工作报告》。2024 年度，公司董事会严格依照《公司法》《证 券法》等法律法规、规范性文件及《公司章程》《董事会议事规则》等制 ...